Latest Content

The authors discuss ways to ensure that accountable care organizations do not bear the cost of inaccurate spending growth predictions.

FDA draft guidance outlines a new pathway to speed up approval of individualized genome and RNA therapies for rare diseases when RCTs are not feasible.

Posters presented during the Conference on Retroviruses and Opportunistic Infections 2026 highlight the safe use of tirzepatide in patients with HIV.

The first full day of CROI 2026 featured a lecture that outlined the next steps in treating and preventing HIV.

FDA approves 4-dose KwikPen for tirzepatide (Zepbound; Eli Lilly), offering a full month of weight management treatment in 1 device.

Safety profiles, efficacy, and lifestyle factors inform shared decision-making and help optimize biologic selection in inflammatory disease management.

SGLT2 inhibitors were associated with significantly lower risks of kidney failure, cardiovascular events, mortality, and hepatic decompensation.

A new study finds higher radiation to key brain stem cell regions in NSCLC brain metastases tied to shorter survival.

Real-world data show vitiligo combination therapy with narrowband UVB or Janus kinase inhibitors drives steeper VASI improvement than monotherapy.